• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人免疫球蛋白的病毒安全性:生产过程对丙型肝炎病毒及其他人类致病病毒的有效灭活

Virus safety of human immunoglobulins: efficient inactivation of hepatitis C and other human pathogenic viruses by the manufacturing procedure.

作者信息

Nowak T, Gregersen J P, Klockmann U, Cummins L B, Hilfenhaus J

机构信息

Research Laboratories of Behringwerke AG, Marburg, Germany.

出版信息

J Med Virol. 1992 Mar;36(3):209-16. doi: 10.1002/jmv.1890360311.

DOI:10.1002/jmv.1890360311
PMID:1314286
Abstract

Human immunoglobulins are plasma derivatives with a low risk of transmitting viral infections. To the present, no proven case of human immunoglobulins transmitting human immunodeficiency viruses has been reported. However, there have been a few reports on the transmission of hepatitis C virus by these plasma proteins. To improve further the safety of both 5s iv human immunoglobulins and 7s im immunoglobulins, we introduced a 10-hour heat treatment of the aqueous solutions at 60 degrees C (i.e., pasteurization) into the manufacturing procedure. This treatment was not added to the manufacturing procedure of 7s iv immunoglobulin that already contained the S-sulfonation as a virus inactivating method. We now report on experimental data that show that the whole manufacturing procedures of the above immunoglobulins inactivate efficiently hepatitis C virus and that the specific virus inactivation methods alone, namely, pasteurization or S-sulfonation, also inactivate completely viruses of the flavivirus family, to which the hepatitis C virus belongs. The inactivation of the Flaviviridae bovine viral diarrhea virus, tick-borne encephalitis virus, and yellow fever virus by pasteurization or S-sulfonation was at least 10(5). The clearance of HCV achieved by the entire manufacturing process of each of these immunoglobulins was also at least 10(5). The experiments therefore show that pasteurization or S-sulfonation provides a high margin of safety to human immunoglobulins regarding the transmission of hepatitis C virus.

摘要

人免疫球蛋白是血浆衍生物,传播病毒感染的风险较低。到目前为止,尚无经证实的人免疫球蛋白传播人类免疫缺陷病毒的病例报告。然而,已有一些关于这些血浆蛋白传播丙型肝炎病毒的报道。为了进一步提高5s静脉用人免疫球蛋白和7s肌内注射免疫球蛋白的安全性,我们在生产过程中引入了在60摄氏度下对水溶液进行10小时热处理(即巴氏灭菌)的步骤。这种处理方法未添加到已采用S-磺化作为病毒灭活方法的7s静脉注射免疫球蛋白的生产过程中。我们现在报告实验数据,这些数据表明上述免疫球蛋白的整个生产过程能有效灭活丙型肝炎病毒,而且单独的特定病毒灭活方法,即巴氏灭菌或S-磺化,也能完全灭活丙型肝炎病毒所属的黄病毒科病毒。通过巴氏灭菌或S-磺化对黄病毒科的牛病毒性腹泻病毒、蜱传脑炎病毒和黄热病毒的灭活率至少为10⁵。这些免疫球蛋白各自的整个生产过程对丙肝病毒的清除率也至少为10⁵。因此,实验表明,就丙型肝炎病毒的传播而言,巴氏灭菌或S-磺化为人免疫球蛋白提供了很高的安全系数。

相似文献

1
Virus safety of human immunoglobulins: efficient inactivation of hepatitis C and other human pathogenic viruses by the manufacturing procedure.人免疫球蛋白的病毒安全性:生产过程对丙型肝炎病毒及其他人类致病病毒的有效灭活
J Med Virol. 1992 Mar;36(3):209-16. doi: 10.1002/jmv.1890360311.
2
Partitioning and inactivation of viruses by the caprylic acid precipitation followed by a terminal pasteurization in the manufacturing process of horse immunoglobulins.在马免疫球蛋白生产过程中,通过辛酸沉淀继以最终巴氏杀菌对病毒进行分离和灭活。
Biologicals. 2007 Oct;35(4):335-41. doi: 10.1016/j.biologicals.2007.02.004. Epub 2007 Apr 30.
3
Inactivation of hepatitis C virus in low pH intravenous immunoglobulin.
Biologicals. 1994 Mar;22(1):13-9. doi: 10.1006/biol.1994.1003.
4
Validation of virus inactivation and removal for the manufacturing procedure of two immunoglobulins and a 5% serum protein solution treated with beta-propiolactone.
Biologicals. 1993 Sep;21(3):259-68. doi: 10.1006/biol.1993.1083.
5
Analysis of human plasma products: polymerase chain reaction does not discriminate between live and inactivated viruses.
Transfusion. 1997 Sep;37(9):935-40. doi: 10.1046/j.1537-2995.1997.37997454021.x.
6
Effective inactivation of a wide range of viruses by pasteurization.通过巴氏杀菌法有效灭活多种病毒。
Transfusion. 2018 Jan;58(1):41-51. doi: 10.1111/trf.14390. Epub 2017 Nov 16.
7
[Inactivation of BVDV (experimental model for hepatitis C) using low pH and heat treatment in intravenous human immunoglobulins].
Sangre (Barc). 1999 Oct;44(5):352-6.
8
Clinical experience with the viral safety of immunoglobulins.免疫球蛋白病毒安全性的临床经验。
Blood Coagul Fibrinolysis. 1994 Dec;5 Suppl 3:S31-4; discussion S35. doi: 10.1097/00001721-199412003-00008.
9
A strategy for testing established human plasma protein manufacturing procedures for their ability to inactivate or eliminate human immunodeficiency virus.
J Biol Stand. 1987 Jul;15(3):251-63. doi: 10.1016/0092-1157(87)90028-x.
10
Virus reduction in the preparation of intravenous immune globulin: in vitro experiments.静脉注射免疫球蛋白制备过程中的病毒去除:体外实验
Transfusion. 1999 Mar;39(3):249-57. doi: 10.1046/j.1537-2995.1999.39399219280.x.

引用本文的文献

1
Effective inactivation of a wide range of viruses by pasteurization.通过巴氏杀菌法有效灭活多种病毒。
Transfusion. 2018 Jan;58(1):41-51. doi: 10.1111/trf.14390. Epub 2017 Nov 16.
2
Safety of snake antivenom immunoglobulins: efficacy of viral inactivation in a complete downstream process.蛇抗毒血清免疫球蛋白的安全性:完整下游工艺中病毒灭活的效果。
Biotechnol Prog. 2013 Jul-Aug;29(4):972-9. doi: 10.1002/btpr.1758. Epub 2013 Jun 27.
3
Inactivation of West Nile virus, vaccinia virus and viral surrogates for relevant and emergent viral pathogens in plasma-derived products.
血浆衍生产品中相关和新出现的病毒病原体的西尼罗河病毒、痘苗病毒及病毒替代物的灭活
Vox Sang. 2004 Jul;87(1):10-8. doi: 10.1111/j.1423-0410.2004.00530.x.
4
Criteria for the appropriate drug utilisation of immunoglobulin.免疫球蛋白合理用药标准。
Pharmacoeconomics. 1996 May;9(5):417-29. doi: 10.2165/00019053-199609050-00005.
5
Human Immunoglobulins for intravenous use and hepatitis C viral transmission.静脉注射用人免疫球蛋白与丙型肝炎病毒传播
Clin Diagn Lab Immunol. 1994 Nov;1(6):613-9. doi: 10.1128/cdli.1.6.613-619.1994.
6
Hepatitis C: progress and problems.丙型肝炎:进展与问题
Clin Microbiol Rev. 1994 Oct;7(4):505-32. doi: 10.1128/CMR.7.4.505.
7
A prospective controlled crossover trial of a new heat-treated intravenous immunoglobulin.一项关于新型热处理静脉注射免疫球蛋白的前瞻性对照交叉试验。
Clin Exp Immunol. 1995 Jan;99(1):10-5. doi: 10.1111/j.1365-2249.1995.tb03465.x.